Actively Recruiting
Study of Blood Markers to Predict Severity in Juvenile Idiopathic Arthritis for Patients 16 and Older
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-09-12
300
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Juvenile idiopathic arthritis JIA is a group of chronic inflammatory rheumatic diseases that start before age 16 and represent the most common pediatric rheumatologic condition. Researchers are studying whether certain serum inflammatory angiogenic markers, such as semaphorins and CCN1 protein, can predict the severity of JIA by assessing structural joint damage and treatment changes. This research builds on previous findings in rheumatoid arthritis where these markers were linked to disease activity and structural harm. The study observes patients with JIA who are followed in a specialized rheumatology consultation, without administering experimental treatments. Blood samples will be collected to measure angiogenic and inflammatory markers over five years. Joint punctures may be performed if required by routine care. Researchers will also gather data on treatments received, structural damage via X-rays, and patient questionnaires at various time points including at the start of the study. Participants will be involved in regular assessments over five years, including blood tests, questionnaires, and imaging to monitor disease progression and biomarker levels. The main focus is on measuring angiogenic and inflammatory markers using methods like ELISA to understand their association with disease severity. This long-term observation aims to improve prediction of JIA outcomes while ensuring patient care continues as usual throughout the study period.
CONDITIONS
Brief Title
Angiogenic Biomarkers in Juvenile Idiopathic Arthritis
Research Team
Y
Yannick ALLANORE, PD, PhD
M
Marie BENHAMMANI-GODARD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here